Skip to content

Study · Animal study (in vivo) · rat · 2019

8 results

Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.

Zhang L, Chopp M, Wang C, Zhang Y, Lu M, Zhang T, Zhang ZG

Journal of the neurological sciences14 Jan 2019Cited by 15 (Europe PMC)

PMID30665068 (opens in a new tab)DOI10.1016/j.jns.2019.01.017 (opens in a new tab)PepBankPUB-30665068
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin significantly improved neurological outcome versus saline.

    In plain wordsIn rats with stroke, Cerebrolysin improved neurological function compared with saline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeurological outcome
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion
    Comparator
    Saline
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®; in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment in comparison to saline as well as to the comparator drug treatment (p < .002).
    3 context sentences
    Summary · context
    Generalized Estimation Equations (GEE) was performed to study the treatment effect on overall functional recovery at day 28 (primary outcome), compared to saline controls.
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats after embolic stroke, Cortexin produced functional outcomes similar to saline control.

    In plain wordsIn rats after embolic stroke, Cortexin produced similar functional recovery to saline.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    No significant changeOverall functional recovery at day 28
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion in male Wistar rats
    Comparator
    saline
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1.7 mg/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®;
    3 context sentences
    Summary · context
    Generalized Estimation Equations (GEE) was performed to study the treatment effect on overall functional recovery at day 28 (primary outcome), compared to saline controls.
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin significantly improved neurological outcome versus Cognistar.

    In plain wordsIn rats with stroke, Cerebrolysin improved neurological function compared with Cognistar.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeurological outcome
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion
    Comparator
    Cognistar
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®; in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment in comparison to saline as well as to the comparator drug treatment (p < .002).
    2 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin significantly improved neurological outcome versus Cerebrolysat.

    In plain wordsIn rats with stroke, Cerebrolysin improved neurological function compared with Cerebrolysat.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeurological outcome
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion
    Comparator
    Cerebrolysat
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®; in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment in comparison to saline as well as to the comparator drug treatment (p < .002).
    2 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin significantly improved neurological outcome versus Cortexin.

    In plain wordsIn rats with stroke, Cerebrolysin improved neurological function compared with Cortexin.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeurological outcome
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion
    Comparator
    Cortexin
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Similar functional outcome was observed for saline control, Cognistar®, Cerebrolysat® and Cortexin®; in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment in comparison to saline as well as to the comparator drug treatment (p < .002).
    2 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Cerebrolysin did not significantly change lesion volume versus saline.

    In plain wordsIn rats with stroke, lesion volume did not differ significantly between Cerebrolysin and saline.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeLesion volume
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 ml/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Measurements

    Lesion volume
    26.5%
    Cerebrolysin
    Lesion volume
    30.8%
    saline

    Source sentences

    Summary
    However, there was no significant difference in lesion volumes between rats treated with either Cortexin® (33.5 ± 1.9%), Cerebrolysat® (28.5 ± 2.4%), Cognistar® (34.7 ± 2.0%), or Cerebrolysin® (26.5 ± 2.3%) compared to saline-treated rats (30.8 ± 2.1%).
    2 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats after embolic stroke, neurological outcomes with Cortexin were worse than with Cerebrolysin.

    In plain wordsIn rats after embolic stroke, Cortexin produced worse neurological outcomes than Cerebrolysin.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseNeurological outcome versus Cerebrolysin
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion in male Wistar rats
    Comparator
    Cerebrolysin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1.7 mg/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    in contrast, a significantly improved neurological outcome was observed with Cerebrolysin® treatment in comparison to saline as well as to the comparator drug treatment (p < .002).
    3 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion and were treated with: 1) Cognistar® (Cerebroprotein Hydrolysate) 2.5 ml/kg, 2) Cerebrolysat® 2.5 ml/kg, 3) Cortexin® 1.7 mg/kg, 4) Cerebrolysin® 2.5 ml/kg, or 5) 1 ml of saline according to a pre-generated randomization plan.
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats after embolic stroke, Cortexin did not significantly change lesion volume versus saline.

    In plain wordsIn rats after embolic stroke, Cortexin did not significantly change lesion volume versus saline.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    No significant changeLesion volume
    Study

    ratn: not reported in source

    Embolic right middle cerebral artery occlusion in male Wistar rats
    Comparator
    saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1.7 mg/kg · intraperitoneal · 10 consecutive daysAs given in this study (rat).

    Measurements

    Lesion volume
    33.5%
    Cortexin
    Lesion volume
    30.8%
    saline

    Source sentences

    Summary
    However, there was no significant difference in lesion volumes between rats treated with either Cortexin® (33.5 ± 1.9%), Cerebrolysat® (28.5 ± 2.4%), Cognistar® (34.7 ± 2.0%), or Cerebrolysin® (26.5 ± 2.3%) compared to saline-treated rats (30.8 ± 2.1%).
    2 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic right middle cerebral artery occlusion
    Summary · context
    All enrolled rats received intraperitoneal injections once daily for 10 consecutive days, starting 4 h after occlusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.